Immunotherapies, notably immune checkpoint inhibitors (ICIs), treat solid tumors by enhancing T cell activation and blocking inhibitory receptors like PD-1 or CTLA-4, strengthening immune attacks on tumor cells [156]. Here, CTLA4 is linked to neoplasm.